Myungmoon Pharm. Co., LTD. (KOSE:A017180) announced a private placement of 18th series unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 15,000,000,000 on January 25, 2019. The transaction includes participation from A1 Type B Grand Prix Hedge Fund, A1 Type B Prime Hedge Fund, A1 Type B Plus Hedge Fund, A1 Premium Hedge Fund, A1 Type B Value Up Hedge Fund, A1 Type B Institutional Mezzanine Hedge Fund, A1 Type B Noble Hedge Fund, A1 Type B Classic Hedge Fund, A1 Mezzanine Plus Hedge Fund, all funds managed by NH Investment & Securities Co., Ltd., Investment Arm for KRW 2,500,000,000, Kiwoom Securities Co., Ltd., Investment Arm for KRW 2,000,000,000, IBK Financial Synergy IB Mezzanine New Technology Fund for KRW 2,000,000,000, and other investors. The bonds carry 1% yield to maturity and do not carry any coupon. The bonds will mature on January 29, 2024. The bonds are 100% convertible at fixed conversion price of KRW 5,576 per share into 2,690,100 shares. The conversion period will start on January 29, 2020 and will end on December 29, 2023. The subscription and the payment date is January 29, 2019. The transaction has been approved by the board of directors of the company.